Epstein-barr virus and hodgkin lymphoma.
Epstein-Barr virus (EBV) is detected in some Hodgkin lymphoma (HL) tumor cells. Primary infection is associated with infectious mononucleosis and EBV(+) HL. Vaccines and antiviral drugs show promise in modulating the clinical course of infectious mononucleosis. Their impact on HL is entirely unknown. T-cell function may be important in the pathogenesis of HL. In HIV patients, higher CD4 counts are associated with an increased incidence of EBV(+) HL. One of the roles of the virus in the pathogenesis of HL may be to mimic signals associated with surface immunoglobulin molecules. New approaches to imaging EBV-associated tumors may be on the horizon. Adoptive immunotherapy and virus-specific pharmacologic therapies offer promise for future treatment.
Ambinder
Richard F
RF
Johns Hopkins University, Bunting-Blaustein Cancer Research Bldg., 1650 Orleans Street, Room 389, Baltimore MD 21231, USA. ambinri@jhmi.edu
D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006689:Hodgkin Disease / Q000150:complications / Q000276:immunology / Q000821:virology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007244:Infectious Mononucleosis / Q000150:complications; D013601:T-Lymphocytes / Q000276:immunology